TWIST1
TWIST1 (twist family bHLH transcription factor 1, also known as Twist-related protein 1, H-twist, SCS, ACS3 and bHLHa38) is a basic helix-loop-helix transcription factor with a central role in embryonic development. It regulates gene expression as a homodimer or as a heterodimer with E proteins. Browse Assay Genie's current range of TWIST1 research reagents below, or read on for the biology behind the target.
TWIST1 acts as a transcriptional regulator. The protein forms both homodimers and heterodimers that bind DNA E box sequences, and its activity depends on dimer composition. Homodimers induce expression of FGFR2 and POSTN, whereas heterodimers with E proteins repress FGFR2 and POSTN and induce THBS1 expression. Heterodimerisation is also required for osteoblast differentiation. Through these mechanisms TWIST1 regulates cranial suture patterning and fusion, and the gene is also thought to contribute to neural tube closure, limb development and brown fat metabolism.
TWIST1 also acts as a repressor in several settings. It inhibits myogenesis by sequestering E proteins, inhibiting MEF2-driven trans-activation and blocking DNA binding by MYOD1 through physical interaction, probably involving the basic domains of both proteins. It represses pro-inflammatory cytokines such as TNF-alpha and IL-1 beta, and it represses the activity of the circadian NPAS2-BMAL1 heterodimer. The protein is localised to the nucleus, and the mouse ortholog is Twist1.
The TWIST1 gene belongs to the basic helix-loop-helix group of proteins. Earlier names reflect its disease associations and origins, including twist homolog 1 (Drosophila), acrocephalosyndactyly 3, craniosynostosis, and blepharophimosis, epicanthus inversus and ptosis 3. Mutations in the gene cause Saethre-Chotzen syndrome, characterised by craniosynostosis, ptosis and hypertelorism. In cancer, the gene is hypermethylated and overexpressed in multiple human tumour types, and the encoded protein promotes tumour cell invasion, metastasis and metastatic recurrence.
TWIST1 regulates cranial suture patterning and fusion, making it central to studies of skull formation and craniosynostosis.
The protein promotes tumour cell invasion, metastasis and metastatic recurrence, and the gene is overexpressed in multiple human cancers.
Dimer composition determines whether TWIST1 induces or represses targets such as FGFR2, POSTN and THBS1, a useful model of bHLH function.
TWIST1 inhibits myogenesis by acting on E proteins, MEF2 and MYOD1, and heterodimerisation is required for osteoblast differentiation.
TWIST1 is a nuclear bHLH transcription factor that regulates gene expression as a homodimer or as a heterodimer with E proteins. It controls cranial suture patterning and fusion, inhibits myogenesis, represses pro-inflammatory cytokines such as TNF-alpha and IL-1 beta, and promotes osteoblast differentiation.
Aliases include SCS, H-twist, BPES2, bHLHa38, CRS1, ACS3, BPES3, TWIST and CRS. Earlier names include twist homolog 1 (Drosophila), acrocephalosyndactyly 3 and craniosynostosis. Many of these reflect the disorders linked to the gene, so searches may use either the symbol or an older name.
Yes. Mutations in the TWIST1 gene cause Saethre-Chotzen syndrome, which features craniosynostosis, ptosis and hypertelorism. The gene is also hypermethylated and overexpressed in multiple human cancers, where the protein promotes invasion and metastasis. The mouse ortholog is Twist1; check the datasheet of any product for its validated reactivity.
Other bHLH partners, TWIST1 target genes, myogenic regulators and circadian and inflammatory factors with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q15672; product specifications from Assay Genie datasheets.